Cstone pharma aktie
WebApr 6, 2024 · CStone Pharmaceuticals Announces NMPA Accepts the Supplemental Biologics License Application for Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma CI Summary
Cstone pharma aktie
Did you know?
WebGet the latest CStone Pharmaceuticals (2616) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … WebOct 12, 2024 · CStone Pharmaceuticals. Oct 11, 2024, 20:05 ET. SUZHOU, China, Oct. 11, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) …
WebCstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of … WebPipeline-CStone Pharmaceuticals. We focus on immuno-oncology and precision medicine with a well-balanced oncology portfolio of 15 innovative assets. Currently, CStone has received 10 NDA approvals for its 4 …
WebMay 28, 2024 · Shanghai - CStone Pharmaceuticals Co., Ltd. ('CStone' or the 'Company', HKEX: 2616) today announced that the company released the pre-clinical data of its three pipeline products, i.e. CS1001 (anti-PD-L1 monoclonal antibody), CS3002 (CDK4/6 selective small molecule inhibitor) and CS3003 (HDAC6 selective small molecule inhibitor), in the … WebJul 18, 2024 · CStone considering sale, says report. 18-07-2024 Print. Chinese biotech firm CStone Pharmaceuticals' (HKEX: 2616) is mulling over a potential sale of the business, according to sources cited by Bloomberg. CStone is exploring strategic options for the future of the enterprise and has drafted in investment bank Goldman Sachs to sound out …
WebJun 7, 2024 · CStone Pharmaceuticals (OTCPK:CSPHF) (2616.HK) revenue fell 77% last year and its net loss climbed, as the Chinese drug company saw one-off license fees decline sharply and marketing costs to ...
WebFunding. CStone Pharmaceuticals has raised a total of $410M in funding over 2 rounds. Their latest funding was raised on May 9, 2024 from a Series B round. CStone Pharmaceuticals is registered under the ticker HKG:2616 . Their stock opened with HK$12.00 in its Feb 25, 2024 IPO. bitefight bgWebFeb 24, 2024 · CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in … dashing installWebMar 13, 2024 · Their share performances varied on Monday, with Broncus Holding Corporation advancing 4% while CStone Pharmaceuticals was down 2.2%. Further supporting sentiment, China reported unexpectedly strong credit growth for February, with money supply expanding at the fastest pace in nearly 7 years, as Beijing looked to … bitefight county 202WebCStone Pharmaceuticals Aktie 20 Jahre Umsatz, Dividende, Realtime-Kurs, EBIT, Gewinn, Ausschüttungsquote, Nettoverschuldung und die besten Aktienanalysen. ... CStone Pharmaceuticals schüttet eine Dividende von NaN über undefined Auschüttungen im … dashing in the snowWebCSTONE PHARMACEUTICALS REGISTERED AKTIE Profil - hier finden Sie alle Informationen über CSTONE PHARMACEUTICALS REGISTERED AKTIE wie z.B. Management, Profil, Aktionärsstruktur und Bilanzdaten. bitefight charismaWebNov 22, 2024 · CStone Pharmaceuticals continues to expand its oncology presence aimed at the Chinese market. On Sunday, the company forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.. Currently, the only anti-CTLA-4 monoclonal antibody that … dashing iq testsWebCSTONE MEDIA For Mainland Chinese Media: Jasmine Yang (MSL) +86 218 025 3296 [email protected] For International Media: Daniel Del Re (Kekst CNC) + 852 9212 3105 [email protected] bitefight cesky